Johnson & Johnson (JNJ) recently reached a preliminary settlement to settle lawsuits against Johnson & Johnson baby powder in more than 40 states.。According to reports, the company will pay $700 million to settle the investigation.。However, the settlement does not address tens of thousands of lawsuits, some of which allege that J & J's Tulkki products cause cancer.。Some of these lawsuits are expected to go to court this year.。Notably, Johnson & Johnson ended its baby powder sales worldwide last year.。

In terms of financial performance, J & J posted strong results for the fourth quarter of 2023。The company's pharmaceutical and medical device business saw a significant increase in sales.。For the full year 2024, Johnson & Johnson forecast sales of $87.8 billion to $88.6 billion and adjusted earnings per share of 10.$55 to $10.75美元。The company reported 137.$200 million in pharmaceutical sales, up 4.2%。During the quarter, the pharmaceutical giant reported 41.$300 million of net income, or EPS 1.$70, compared to 32.Net income or EPS of $300 million 1.22 USD。Analyst's 12-month average price target for J & J's stock is 178.$08, with a maximum forecast of 215.$00, minimum forecast of 160.00 美元。J & J shows solid momentum in performance and settlement, but faces unresolved legal challenges。